What's Driving Broadwood Partners' Deep Dive into STAAR Surgical
Activist investor Broadwood Partners is significantly increasing its stake in STAAR Surgical, investing over $12 million recently, following a prior $8.8 million investment, despite rejecting a $1.6 billion acquisition offer from Alcon. Broadwood, now effectively controlling the boardroom, believes STAAR's fundamentals are improving, with an anticipated return to growth and profitability from 2026 onwards. However, STAAR faces considerable challenges including a significant TTM revenue decline, negative profitability, and persistent macroeconomic headwinds in China, leading to a consensus "Reduce" rating from analysts.
STAA stock on track for its fourth straight session of gains – this analyst would rather be early than late on STAAR’s growth story
The article discusses STAAR Surgical Company (STAA) stock, which is showing a fourth consecutive session of gains. An analyst has upgraded STAAR stock to a Buy rating, indicating a strong belief in the company's future growth potential in the ophthalmic market. The analyst highlighted STAAR's position to capitalize on the increasing adoption of implantable contact lenses, suggesting strong growth prospects despite current market skepticism.
STAAR Surgical Announces Participation in Upcoming Investor Conferences
STAAR Surgical Company (NASDAQ: STAA) announced that its management will participate in two upcoming investor conferences: the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, and a Canaccord Genuity Virtual Fireside Chat on May 27, 2026. Participation for investor meetings is by invitation only, but webcasts for both events will be available on STAAR’s investor website. The company is a global leader in phakic IOLs with its EVO family of Implantable Collamer Lenses for vision correction.
Vision-correction lens maker STAAR hosts May investor talks
STAAR Surgical Company (NASDAQ: STAA) announced its participation in two upcoming investor conferences in May 2026. Management will join the Stifel 2026 Virtual Ophthalmology Forum on May 26 and a Canaccord Genuity Virtual Fireside Chat on May 27, primarily for investor meetings by invitation and webcasts. These events provide an opportunity for investors to learn more about the company, which is a global leader in phakic IOLs for vision correction.
5 must-read analyst questions from STAAR Surgical’s Q1 earnings call
This article highlights key analyst questions from STAAR Surgical's Q1 earnings call. It focuses on inquiries about the company's financial performance, market strategy, and future outlook, providing insights into investor concerns and management responses.
5 Must-Read Analyst Questions From STAAR Surgical’s Q1 Earnings Call
STAAR Surgical reported strong Q1 results, exceeding analyst expectations for revenue, EPS, and EBITDA, attributed to robust sales in China and the EVO+ lens launch. The company's interim Co-CEO noted that operational disruptions from 2025 are largely resolved. Key analyst questions focused on China's market seasonality and competition, inventory levels, and ex-China growth prospects following the expanded U.S. age indication.
STAAR Surgical Q1 2026 Results: Revenue Up 120%, EPS Beats Estimates - News and Statistics
STAAR Surgical announced strong Q1 2026 results, exceeding Wall Street's revenue and EPS forecasts with a 120% sales jump to $93.52 million and non-GAAP EPS of $0.29. The company attributed this success to robust sales in China, early demand for the EVO+ lens, normalized inventory levels, and improved operational efficiencies. Management is cautious about providing short-term guidance but sees continued growth drivers, including expanded U.S. market access and scaling of its Swiss manufacturing facility.
STAAR Surgical (STAA) interim Co-CEO receives PSUs and share tax withholding
STAAR Surgical's interim Co-CEO and CFO, Deborah J. Andrews, reported equity compensation activity related to performance stock units (PSUs) that vested on May 15, 2026. Two tranches of PSUs, totaling 15,699 shares, settled into common stock after performance certification. To cover tax obligations, 5,632 shares were withheld at approximately $32.07 per share, resulting in Andrews directly holding 15,297 shares of STAAR Surgical common stock.
STAAR Surgical (STAA) Is Up 15.2% After EVO+ China Surge Drives Sharp Q1 Profit Rebound – Has The Bull Case Changed?
STAAR Surgical (STAA) reported a significant Q1 2026 profit rebound, with net sales surging to US$93.52 million and achieving a net income of US$5.21 million, primarily driven by strong demand for EVO+ lenses in China and expanded U.S. indications. This performance bolsters the company's investment narrative, emphasizing its potential in lens-based refractive surgery, though it remains exposed to China market volatility and regulatory risks. Despite the positive quarter, the company's fair value is estimated at $21.11, suggesting a 34% downside from its current price, and its strong dependence on China means investors should remain aware of potential policy shifts.
STAAR Surgical (STAA) Is Up 15.2% After EVO+ China Surge Drives Sharp Q1 Profit Rebound – Has The Bull Case Changed?
STAAR Surgical experienced a significant Q1 2026 profit rebound, primarily driven by resurgent demand for its EVO+ lenses in China. This surge, coupled with expanding U.S. indications and cost control measures, transformed the company's profitability. While this bolsters the China recovery story and broadens STAAR's market, the article cautions that the company remains highly dependent on the Chinese market and its associated risks.
GABELLI & Co INVESTMENT ADVISERS INC. Sells 40,000 Shares of STAAR Surgical Company $STAA
GABELLI & Co. Investment Advisers reduced its stake in STAAR Surgical Company by 22.3% in the fourth quarter, selling 40,000 shares. Despite this, STAAR Surgical reported a strong Q1 earnings beat, exceeding revenue estimates by 119.6% year-over-year. Analyst sentiment has shown improvement with several upgrades and higher price targets, though the consensus remains a Hold due to some lingering caution.
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company reported a strong Q1 2026, with revenue up 119% year-over-year to $93.5M and a net income of $5.2M, driven by China’s market recovery and increased adoption of EVO+ ICL. The company is benefiting from a shift towards lens-based refractive surgery and U.S. market share gains. Despite an elevated valuation, the results suggest potential for sustained growth and margin expansion.
STAAR Surgical (STAA) Returns To Quarterly Profit In Q1 2026 Challenging Bearish Profitability Concerns
STAAR Surgical (STAA) posted a quarterly profit in Q1 2026 with US$93.5 million in revenue and basic EPS of US$0.10, despite a trailing twelve-month loss of US$21.0 million. The company's profitability has been inconsistent, oscillating between gains and losses. Analysts forecast a path to profitability within three years, but current valuation is considered rich compared to industry averages and fair value models.
STAAR Surgical Company Stock 12‑Month Price Target Raised to $28.11, Implies 4% Downside
STAAR Surgical Company's average 12-month price target has been raised from $23 to $28.11 by nine analysts, indicating a potential 4% downside from its May 13 closing price. The consensus rating for the stock has shifted to "Buy," with 11 analysts covering it, including 3 Buys and 8 Holds.
Staar Surgical Faces Heightened Uncertainty as Interrelated Risk Factors Threaten Future Performance and Valuation
Staar Surgical Company (STAA) has disclosed new regulation-related risk factors in its Form 10-K for the fiscal year ended January 2, 2026. These diverse and interrelated external factors could significantly impact the firm's business, financial condition, and operating results, leading to increased earnings volatility and potentially negative investor confidence. Wall Street currently holds a Hold consensus rating on STAA stock.
A Look at Staar Surgical Co (STAA) After 8.9% Gain -- GF Value $29.35 vs Price $32.01
Staar Surgical Co (STAA) shares rose 8.9% to $32.01, indicating an 83.7% increase over the past year. Despite strong momentum and notable insider buying of $12.3 million, the stock is considered 9.1% overvalued according to GuruFocus' GF Value of $29.35. Investors are cautioned due to this overvaluation, despite an above-average GF Score of 79/100, which points to potential for higher long-term returns.
STAAR Surgical Reports Record First Quarter 2026 Financial Results
STAAR Surgical Company reported record financial results for the first quarter of 2026, with net sales reaching $93.5 million, a 119.6 percent increase year-over-year. This growth was primarily driven by strong performance in China and double-digit growth in the Americas, leading to a net income of $5.2 million compared to a net loss in the prior year. The company also highlighted improved gross profit margins and reduced operating expenses, alongside an expanded FDA age indication for its EVO/EVO+ Visian ICL product.
Staar Surgical Company stock hits 52-week high at 35.7 USD
Staar Surgical Company (STAA) stock recently hit a 52-week high of $35.70, currently trading at $34.70 with a market capitalization of $1.46 billion. This surge reflects strong investor confidence, with the stock gaining 69% over the past year and 27% year-to-date. The company's recent Q1 2026 financial results surpassed revenue and earnings forecasts, driven by strong performance in its China business, leading to positive analyst reactions and increased price targets.
STAA Q1 Deep Dive: China Momentum, Cost Discipline, and Stabilized Inventory Drive Turnaround
STAAR Surgical (STAA) reported strong Q1 CY2026 results, surpassing revenue and EPS estimates due to robust sales in China, the successful launch of its EVO+ lens, and stabilized inventory levels. The company's turnaround is attributed to improved operational execution and cost discipline, leading to a return to profitability. While optimistic about continued growth, particularly in China and the U.S. market, management remains cautious about macroeconomic uncertainties and has refrained from providing formal forward-looking guidance.
STAAR Surgical (STAA) Q1 2026 Earnings Transcript
STAAR Surgical (STAA) reported a significant improvement in its Q1 2026 financial results, with net sales increasing by 119.6% to $93.5 million, largely driven by strong demand for its EVO+ ICL in China and double-digit growth in the Americas. The company achieved a positive adjusted EBITDA of $24.4 million, reversing a previous loss, and a net income of $5.2 million. STAAR Surgical emphasized its focus on operational discipline, manufacturing scalability, and innovative product expansion, while remaining cautious about providing full-year guidance due to macroeconomic uncertainties.
Vanguard Group Inc. Sells 42,560 Shares of STAAR Surgical Company $STAA
Vanguard Group Inc. reduced its stake in STAAR Surgical Company by selling 42,560 shares, bringing its total to 4.23 million shares. Simultaneously, insider buying increased significantly, with Director Broadwood Partners acquiring over 316,000 shares, and insiders collectively purchasing 670,213 shares totaling $12.3 million over 90 days. STAAR Surgical also reported strong quarterly results, exceeding EPS and revenue expectations, and the stock was up 4.3% on the day.
STAAR Surgical Company Stock 12‑Month Price Target Raised to $28.11, Implies 4% Downside
STAAR Surgical Company's average 12-month price target has been increased to $28.11 from $23, according to 9 analysts. This new target implies a 4% potential downside from the May 13 closing price. The consensus analyst rating for the stock has shifted to "Buy."
STAAR Surgical Company Stock 12‑Month Price Target Raised to $23.56, Implies 20% Downside
STAAR Surgical Company's average 12-month price target has increased to $23.56 from $21.11, according to estimates from nine analysts. Despite the raised target, this implies a potential 20% downside based on the May 13 closing price. The consensus rating for the stock remains "Hold" among eleven covering analysts.
STAAR Surgical Reports Record First Quarter 2026 Financial Results
STAAR Surgical Company reported record financial results for the first quarter of 2026, with net sales reaching $93.5 million, a 119.6 percent increase year-over-year. This growth was driven primarily by strong performance in China and double-digit growth in the Americas, leading to a net income of $5.2 million compared to a loss in the prior year. The company's interim co-CEOs highlighted progress in manufacturing, an expanded FDA age indication for their EVO ICLs, and a focus on consistent, profitable growth despite global economic uncertainties.
STAAR Surgical (NASDAQ:STAA) Beats Expectations in Strong Q1 CY2026, Stock Jumps 18.3%
STAAR Surgical (NASDAQ:STAA) reported strong Q1 CY2026 results, surpassing analysts' revenue and EPS estimates with a 120% year-on-year sales increase to $93.52 million and a GAAP profit of $0.10 per share. The company's adjusted EBITDA also significantly beat expectations, and the stock jumped 18.3% immediately after the report. Despite past revenue declines, analysts anticipate a 7.1% revenue growth over the next 12 months, driven by new products.
Eye implant maker STAAR swings to Q1 profit on record $93.5M sales
STAAR Surgical (NASDAQ: STAA) reported a strong first quarter in 2026, swinging to a net profit of $5.2 million on record net sales of $93.5 million, an increase of 119.6% year-over-year. The company achieved this by improving operational execution, returning to profitability in China with strong EVO+ ICL launches, and experiencing double-digit sales growth in the U.S., despite a challenging global economic environment. STAAR Surgical remains focused on revenue growth, profit expansion, and innovation acceleration, anticipating continued success in the lens-based refractive surgery market.
Staar Surgical: Q1 Earnings Snapshot
Staar Surgical Co. (STAA) reported a first-quarter profit of $5.2 million, or 10 cents per share. After adjusting for certain costs, earnings were 38 cents per share, significantly exceeding Wall Street's expectation of 13 cents per share. The company, which manufactures implantable lenses, also posted revenues of $93.5 million for the period.
Earnings Flash (STAA) STAAR Surgical Company Reports Q1 Revenue $93.5M, vs. FactSet Est of $78.7M
STAAR Surgical Company (STAA) announced strong first-quarter revenue of $93.5 million, significantly surpassing FactSet's estimated $78.7 million. This financial beat indicates a positive performance for the medical equipment company, which specializes in implantable lenses for vision correction. The news was published on May 13, 2026, at 04:04 pm EDT by MT Newswires.
Earnings Flash (STAA) STAAR Surgical Company Reports Q1 Revenue $93.5M, Vs. FactSet Est of $78.7M
STAAR Surgical Company (STAA) announced its first quarter revenue reached $93.5 million, significantly exceeding the FactSet estimate of $78.7 million. This strong performance indicates better-than-expected financial results for the company in Q1.
STAAR Surgical faces earnings test on China demand durability
STAAR Surgical is set to report its first-quarter results, with investors keenly focused on the sustainability of its revenue rebound in China. Analysts are also watching profitability metrics, especially gross margins, and awaiting 2026 guidance after the company terminated its merger agreement with Alcon. The company's performance in China is crucial due to the country accounting for a significant portion of regional demand for its implantable lenses.
SCHEDULE 13G] STAAR SURGICAL CO Passive Investment Disclosure (>5%)
Point72 Asset Management and related entities have disclosed a 5.2% beneficial ownership stake in STAAR Surgical Company (STAA) as of May 11, 2026. This Schedule 13G filing indicates shared voting and dispositive power over 2,591,498 shares of common stock, held in investment funds managed by Point72. The disclosure serves as a transparency measure regarding significant ownership in public companies and states that the shares were not acquired to influence control of the issuer.
STAAR Surgical (STAA) CDO has shares withheld for RSU tax payment
STAAR Surgical's Chief Development Officer, Magda Michna, reported a tax-related disposition of 1,680 common shares on May 8, 2026. These shares, valued at $26.69 each, were withheld to cover taxes on previously granted restricted stock units (RSUs) that vested on that date. After this transaction, Michna directly holds 32,691 shares, and the filing also corrected a previous typo in her reported holdings.
STAAR Surgical Co stock (US8577001096): Up 2.35% among top monthly gainers
STAAR Surgical Co (STAA) shares rose 2.35% in May 2026, positioning it among the month's top-performing healthcare stocks. The company, known for its Implantable Collamer Lenses (ICL), trades at $27.83 with a market capitalization of $1.39 billion. Its core business focuses on vision correction through minimally invasive ophthalmic products, with ICL implants accounting for over 90% of net sales, particularly driven by international markets like China and Japan.
Earnings To Watch: STAAR Surgical (STAA) Reports Q1 Results Tomorrow
STAAR Surgical (STAA) is set to report its Q1 results this Wednesday, with the market expecting an 81.8% year-on-year revenue growth. This comes after the company missed analysts' revenue and EPS estimates last quarter. Analysts have grown more bearish recently, although the medical devices & supplies - specialty segment has seen positive investor sentiment.
A Look At STAAR Surgical (STAA) Valuation As Earnings Are Expected To Swing From Loss To Profit
STAAR Surgical (STAA) is garnering attention as it anticipates a shift from loss to profit in its upcoming first-quarter earnings report. Despite a significant 90-day share price increase, analysts disagree on its current valuation, with some deeming it overvalued at $21.11 and others seeing a fairer price closer to $27.53 based on discounted cash flow models. Investors are advised to examine the underlying assumptions and risks, such as China-dependent revenue and single-distributor reliance, before the earnings announcement.
STAAR Surgical (STAA) Q1 2026 Preview: EPS Est. $0.08, Reports May 13
STAAR Surgical (STAA) is expected to report first-quarter fiscal 2026 results on May 13, with Wall Street anticipating sequential improvement. The consensus among analysts is for earnings of $0.08 per share on revenue of $78.7 million, marking a significant turnaround from a loss of $0.53 per share on revenue of $42.6 million in Q1 2025. Investors will be looking for evidence of sustainable revenue acceleration and margin recovery, as well as insights into product volumes, pricing, and the competitive landscape in the ophthalmic surgical device market.
STAAR Surgical will post Q1 results May 13 and host a 5:30 p.m. ET webcast
STAAR Surgical (NASDAQ: STAA) announced it will release its first-quarter 2026 financial results and a shareholder letter on Wednesday, May 13, 2026, after market close. The company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial performance, strategic priorities, and market trends, including those in China. A replay of the webcast will be available for 90 days.
STAAR Surgical earnings loom: Can China recovery prove durable?
STAAR Surgical is set to report its first-quarter results, with investors keenly focused on the sustainability of its China recovery and overall profitability. While preliminary sales figures exceeded expectations, analysts remain cautious regarding the durability of China's demand, the lack of full-year guidance, and the company's path to improved profitability. The company operates in a growing market for implantable collamer lenses, offering an alternative to LASIK.
STAAR Surgical earnings loom: Can China recovery prove durable?
STAAR Surgical is set to report its first-quarter results, with analysts and investors focused on the sustainability of its recovery in China and overall profitability. While preliminary Q1 sales showed a significant rebound, concerns linger about whether this is a temporary inventory correction or genuine demand. The company's lack of full-year guidance and the need for improved profitability are key factors investors will be watching.
Precision Trading with Staar Surgical Company (STAA) Risk Zones
This article provides a precision trading analysis for Staar Surgical Company (STAA), highlighting strong near and mid-term sentiment and a mid-channel oscillation pattern. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal insights and details an exceptional risk-reward short setup.
STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026
STAAR Surgical (NASDAQ: STAA) announced it will release its first quarter 2026 financial results and host an earnings call and webcast on Wednesday, May 13, 2026, after market close. The call will discuss financial results, business progress, strategic priorities, revenue growth, profit expansion, innovation, and dynamics in key markets like China. Investors can access the live webcast and replay through the company's investor relations website.
[ARS] STAAR SURGICAL CO SEC Filing
This article announces an ARS SEC filing by STAAR Surgical Co. (STAA) made on May 4, 2026, accessible as a PDF document. The filing is noted to have a low impact and neutral sentiment. The article also provides recent news and other SEC filings for STAAR Surgical, along with key stock data.
STAAR Surgical (STAA) Projected to Post Earnings on Wednesday
STAAR Surgical (STAA) is expected to announce its Q1 2026 earnings on Wednesday, May 6th, with analysts projecting $0.12 EPS and $67.58 million in revenue. This follows a disappointing prior quarter where the company missed estimates, reporting a -$0.37 loss per share against a $0.14 estimate, and revenue of $57.8M versus $75.54M. Despite a negative net margin, insider buying has accelerated, and analysts currently hold a consensus "Hold" rating with a target price of $19.93.
Staar Surgical Co (STAA) Shares Surge 3.9% -- What GF Score of 74 Tells Investors
Staar Surgical Co (STAA) shares surged 3.9% on April 27, 2026, and are up 49.1% over the past month. The stock is considered 8.1% undervalued based on its GF Value™ of $29.03 against a current trading price of $26.68. Insiders have shown strong confidence by purchasing $12.3 million worth of shares in the last three months, contributing to the company's overall GF Score™ of 74/100, though potential investors should note the high forward P/E and low momentum rank.
Staar Surgical Co (STAA) Shares Surge 3.9% -- What GF Score of 74 Tells Investors
Staar Surgical Co (STAA) shares surged 3.9% on April 27, 2026, closing at $26.68, marking a 49.1% increase over the past month. Despite a high historical 5-Year Median P/E of 106.6x and a forward P/E of 860.6x, GuruFocus considers STAA undervalued with a GF Value™ of $29.03. Insiders have shown strong confidence with $12.3 million in share purchases over the last three months, and the company holds a GF Score™ of 74/100, although its momentum rank is low.
STAAR Surgical announces preliminary net sales for first quarter 2026
STAAR Surgical announced its preliminary net sales for the first quarter of 2026. The company expects these preliminary figures to provide an early indication of its financial performance for the period.
STAAR Surgical sinks as it plans to terminate sale to Alcon (update)
STAAR Surgical (STAA) shares are falling after the company announced its intention to terminate the acquisition agreement with Alcon (ALC). The decision comes as Alcon has not obtained all necessary antitrust approvals by the outside date specified in the agreement, leading STAAR Surgical to seek a termination fee.
STAAR Surgical Company (NASDAQ:STAA) Receives Average Recommendation of "Hold" from Brokerages
STAAR Surgical Company (NASDAQ:STAA) has an average "Hold" recommendation from eleven brokerages, with a mean 12-month price target of $19.93. Despite recent significant insider and institutional buying, the company missed Q and revenue expectations, resulting in negative net margin and return on equity. Several analysts have adjusted their price targets and ratings based on recent performance.
BlackRock (NASDAQ: STAA) holds 6.51M shares, 13.1% stake in STAAR SURGICAL CO
BlackRock, Inc. has filed an amended Schedule 13G to disclose its beneficial ownership of 6,507,911 shares of STAAR SURGICAL CO common stock, which represents a 13.1% stake in the company as of March 31, 2026. The filing indicates that BlackRock holds 6,453,653 shares with sole voting power and that iShares Core S&P Small-Cap ETF holds more than 5% interest in the issuer's common stock. This is considered a passive institutional disclosure.
Why Did STAAR Surgical (STAA) Stock Jump 20% After Hours?
STAAR Surgical (STAA) stock surged over 20% in after-hours trading after reporting preliminary first-quarter 2026 net sales exceeding $90 million, a significant increase from the previous year. This growth was primarily driven by strong performance in China and the Americas, leading to improved adjusted EBITDA. Despite geopolitical challenges impacting other regions, the company highlighted progress on its revenue growth and profit expansion objectives.
